Please login to the form below

pharma business models

This page shows the latest pharma business models news and features for those working in and with pharma, biotech and healthcare.

Gradually, then suddenly

My research on how our changing industry environment is driving the evolution of pharma and medtech business models always seems to create enough cognitive dissonance in the group to break the ... models become ‘unfit’, in the evolutionary sense of

Latest news

A butterfly flaps its wings

And, like all environmental changes, it will create opportunities and threats for existing business models. ... This creates an opportunity for pharma and medtech business models for whom affluent consumers are the primary target market; these need not
Managing pharma's uncertainty

Response to external forces by reactive adaptation in proportion to impact on current business. ... Shaping of controllable external forces by early, proactive engagement in proportion to impact on future business.
Pharma investment in marketing flat in 2013

In a sign of pharma's changing business models, new data has demonstrated that the industry's investment in sales force and marketing channels was flat at just under 85bn for ... In the last six months of 2013, all digital channels tracked by CSD,
Sex is a good trick

Market access is a co-evolutionary problem. Payer systems and industry business models are tied together in a co-evolutionary process in which change in one is both restricted and encouraged ... But what do we observe when pharma companies try to develop
Hollow victory: the dangers of success

In our research about how pharma companies are adapting to a changing market, the capacity of firms to change is obviously an important factor. ... Even the most successful pharma companies risk being overtaken by their less successful followers .

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Creating value from value-based healthcare

Why pharma companies need to implement novel business models and more. ... The companies that are able to identify the systems and stakeholders willing to pay for both outcomes and savings on total costs will be able to implement novel business models,.
Lonely planet: why there is dwindling value in pharma travelling alone

To develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward. ... Published in 2009, Pharma 2020: Challenging Business Models argued that pharma would need to collaborate with academic
Managing medication non-adherence

In this era of value-based payment models becoming mainstream, this is certainly a triple whammy of benefits for all pharma companies to aim for. ... When the business models are sufficiently attractive for the pharma companies to take notice, narrowband
Healthcare business and operating models redefined

They must realise the fundamental impact new business models will have on their organisations. ... Emerging business models . Meanwhile, new business models which incorporate fundamentally different economics are solidifying.
Digital Business Models

But life sciences companies must design and build entirely new business models that embrace digital. ... They must take a fresh look at their capabilities and business models and find entirely new ways to meet the needs of consumers.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

Mueller Hale Consulting

We generate Pharma Business Case Models to evaluate commercial opportunities and execute strategies as project and interim managers.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The search for treatments for Parkinson’s disease: The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.: Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials: As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...